Literature DB >> 19596932

Insulin-like growth factor-binding protein-3 in osteosarcomas and normal bone tissues.

Sigrun Ressler1, Jasim Radhi, Thomas Aigner, Christine Loo, Werner Zwerschke, Consolato Sergi.   

Abstract

BACKGROUND: To better understand the significance of local insulin-like growth factor-binding protein 3 (IGFBP-3) in the development of osteosarcoma, IGFBP-3 levels and subcellular localization were compared in biopsies from osteosarcomas and unaffected normal bone tissues. PATIENTS AND METHODS: IGFBP-3 levels were analyzed by immunohistochemistry in 21 osteosarcomas and 5 unaffected bone tissues. IGFBP-3 levels were compared for patient outcome.
RESULTS: Mature osteocytes of normal bone tissues contained high levels of predominantly nuclear IGFBP-3, whereas only 50% of osteosarcomas contained IGFBP-3-positive tumor cells, with predominantly cytoplasmic IGFBP-3 staining. Comparison of IGFBP-3 levels for patient outcome resulted in two groups. Patients with a low level of IGFBP-3 in osteosarcoma experienced a trend for a shorter survival time than did patients with a high level of IGFBP-3.
CONCLUSION: Our results suggest that the levels and subcellular localization of local IGFBP-3 play a role in osteosarcoma development. Further prospective evaluation with higher clinical sample numbers might reveal a prognostic role for IGFBP-3 level in local tumors in patients with osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596932

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Investigation of insulin resistance gene polymorphisms in patients with differentiated thyroid cancer.

Authors:  Mustafa Akker; Sibel Güldiken; Tammam Sipahi; Orkide Palabıyık; Ayhan Tosunoğlu; Özlem Çelik; Nermin Tunçbilek; Atakan Sezer; Necdet Süt
Journal:  Mol Biol Rep       Date:  2014-02-07       Impact factor: 2.316

Review 2.  Growth hormone, the insulin-like growth factor axis, insulin and cancer risk.

Authors:  Peter E Clayton; Indraneel Banerjee; Philip G Murray; Andrew G Renehan
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

3.  Commentary on: SMARCB1 as a novel diagnostic and prognostic biomarker for osteosarcoma.

Authors:  Consolato M Sergi
Journal:  Biosci Rep       Date:  2022-06-30       Impact factor: 3.976

4.  Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).

Authors:  Andrés Redondo; Silvia Bagué; Daniel Bernabeu; Eduardo Ortiz-Cruz; Claudia Valverde; Rosa Alvarez; Javier Martinez-Trufero; Jose A Lopez-Martin; Raquel Correa; Josefina Cruz; Antonio Lopez-Pousa; Aurelio Santos; Xavier García Del Muro; Javier Martin-Broto
Journal:  Cancer Chemother Pharmacol       Date:  2017-10-16       Impact factor: 3.333

5.  Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy.

Authors:  Sohel M Julovi; Janet L Martin; Robert C Baxter
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-22       Impact factor: 5.555

6.  HPA axis genetic variation, cortisol and psychosis in major depression.

Authors:  A F Schatzberg; J Keller; L Tennakoon; A Lembke; G Williams; F B Kraemer; J E Sarginson; L C Lazzeroni; G M Murphy
Journal:  Mol Psychiatry       Date:  2013-10-29       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.